Upstream Bio (UPB) EPS (Weighted Average and Diluted) (2023 - 2026)
Upstream Bio (UPB) recorded quarterly EPS (Weighted Average and Diluted) of -$0.75 in Q1 2026, up 3.85% quarter-over-quarter from -$0.78 in Q4 2025, and down 47.06% on a YoY basis from -$1.42 in Q1 2025.
Upstream Bio (UPB) EPS (Weighted Average and Diluted) (2023 - 2026) Analysis & Trends
Upstream Bio's EPS (Weighted Average and Diluted) history runs 4 years deep, the most recent figure standing at -$0.75 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 47.06% year-over-year to -$0.75; the TTM figure through Mar 2026 stood at -$2.9 (down 107.14% YoY), while the FY2025 annual figure was -$2.66, up 52.33% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.75 for Q1 2026 at Upstream Bio, up from -$0.78 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $12.57 in Q4 2024 to a low of -$6.96 in Q3 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$1.47 across 4 years, with a median of -$0.78 in 2025.
- Biggest YoY gain for EPS (Weighted Average and Diluted) was 348.91% in 2024; the steepest drop was 229.86% in 2024.
- A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$5.05 in 2023, then jumped by 348.91% to $12.57 in 2024, then plunged by 106.21% to -$0.78 in 2025, then gained by 3.85% to -$0.75 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.75 (Q1 2026), -$0.78 (Q4 2025), and -$0.63 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Upstream Bio | 339.03 Mn | 339.03 Mn | -3.94 Mn | -0.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.75 |
| Dec 31, 2025 | -0.78 |
| Sep 30, 2025 | -0.63 |
| Jun 30, 2025 | -0.74 |
| Mar 31, 2025 | -0.51 |
| Dec 31, 2024 | 12.57 |
| Sep 30, 2024 | -6.96 |
| Jun 30, 2024 | -6.50 |
| Mar 31, 2024 | -4.68 |
| Dec 31, 2023 | -5.05 |
| Sep 30, 2023 | -2.11 |